1147077-78-8Relevant articles and documents
Design and characterization of optimized adenosine A2A/A 1 receptor antagonists for the treatment of Parkinson's disease
Shook, Brian C.,Rassnick, Stefanie,Wallace, Nathaniel,Crooke, Jeffrey,Ault, Mark,Chakravarty, Devraj,Barbay, J. Kent,Wang, Aihua,Powell, Mark T.,Leonard, Kristi,Alford, Vernon,Scannevin, Robert H.,Carroll, Karen,Lampron, Lisa,Westover, Lori,Lim, Heng-Keang,Russell, Ronald,Branum, Shawn,Wells, Kenneth M.,Damon, Sandra,Youells, Scott,Li, Xun,Beauchamp, Derek A.,Rhodes, Kenneth,Jackson, Paul F.
scheme or table, p. 1402 - 1417 (2012/04/04)
The design and characterization of two, dual adenosine A 2A/A1 receptor antagonists in several animal models of Parkinson's disease is described. Compound 1 was previously reported as a potential treatment for Parkinson's disease. Fu
ARYLINDENOPYRIMIDINES WITH REDUCED hERG CHANNEL BINDING
-
, (2012/01/13)
This invention provides novel arylindenopyrimidines of the Formula (I), and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by antagonizing adenosine A1 and/or A2a receptors. This invention also provides therapeutic
Methylene amine substituted arylindenopyrimidines as potent adenosine A2A/A1 antagonists
Shook, Brian C.,Rassnick, Stefanie,Hall, Daniel,Rupert, Kenneth C.,Heintzelman, Geoffrey R.,Hansen, Kristen,Chakravarty, Devraj,Bullington, James L.,Scannevin, Robert H.,Magliaro, Brian,Westover, Lori,Carroll, Karen,Lampron, Lisa,Russell, Ronald,Branum, Shawn,Wells, Kenneth,Damon, Sandra,Youells, Scott,Li, Xun,Osbourne, Mel,Demarest, Keith,Tang, Yuting,Rhodes, Kenneth,Jackson, Paul F.
scheme or table, p. 2864 - 2867 (2010/07/06)
A novel series of arylindenopyrimidines were identified as A2A and A1 receptor antagonists. The series was optimized for in vitro activity by substituting the 8- and 9-positions with methylene amine substituents. The compounds show excellent activity in mouse models of Parkinson's disease when dosed orally.
